A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma

Trial Profile

A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs Ibrutinib (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 30 Mar 2016 Planned primary completion date changed from 1 Apr 2023 to 1 Mar 2023 as reported by ClinicalTrials.gov.
    • 30 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top